Leadership in antibody-drug conjugate development
Seattle Genetics is leading the field in developing antibody-drug conjugates (ADCs). ADCs are empowered antibodies designed to harness the targeting ability of monoclonal antibodies by linking them to cell-killing agents.
For more than 20 years, engineered monoclonal antibodies have provided therapeutic benefit to people with cancer, autoimmune diseases and other serious medical conditions. Early antibody-based therapies revolutionized the treatment of cancer by targeting malignant cells and limiting damage to normal tissue. This resulted in therapies that were better tolerated and could be used in combination with chemotherapy to improve patient outcomes without significant increases in toxicities.
While engineered antibodies have provided clinical benefit in several disease indications, many antibodies lack sufficient intrinsic antitumor activity to be used as therapeutics. Seattle Genetics has developed proprietary, industry-leading technology that is the next step in therapeutic antibody-based therapies. Our ADC technology combines the specificity of engineered antibodies with the potent cell-killing effects of chemotherapy.
First FDA-Approved CD30-Directed ADC
ADCETRIS® (brentuximab vedotin), our lead ADC program, was granted accelerated approval by the U.S. Food and Drug Administration (FDA) in August 2011, validating the therapeutic utility of this technology. Health Canada granted approval with conditions to us in February 2013. Additionally, the European Commission granted Millennium conditional marketing authorization for ADCETRIS in October 2012.
ADCETRIS is an ADC comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing our proprietary technology. The ADC employs a linker system that is designed to be stable in the bloodstream but to release MMAE upon internalization into CD30-expressing tumor cells. We are also advancing SGN-75, an ADC targeting CD70, SGN-CD19A, an ADC targeting CD19, SGN-CD33A, an ADC targeting CD33, as well as ASG-22ME and ASG-15ME, ADCs that we are co-developing with Agensys.
Driving the Field of ADCs
In parallel to advancing our auristatin-based technology through Seattle Genetics internal and collaborator programs, we have significant research efforts to continue driving the field of ADCs.